UPDATE : Monday, February 17, 2020
상단여백
Pharma industry urges deregulation to develop new drug using AI by Jeong Sae-im 2019-06-05 11:53
FDA OKs phase-1 trial for Yuhan’s investigational lung cancer drug by Jeong Sae-im 2019-06-04 14:21
Kolon’s minority shareholders demand over ₩25 billion in damage by Jeong Sae-im 2019-06-03 14:53
Invossa inventor sold Kolon shares at highest value by Jeong Sae-im 2019-06-03 14:52
Hanmi’s hypertension drug was effective in phase-4 study  by Jeong Sae-im 2019-05-31 16:05
라인
Until when will Kolon keep lying about Invossa? by Jeong Sae-im 2019-05-31 14:59
Samsung BioLogics agrees to manufacture CytoDyn’s HIV drug by Jeong Sae-im 2019-05-31 14:59
Announcement of Invossa license revocation was ‘procedural breach’: Kolon by Jeong Sae-im 2019-05-30 13:28
Medytox suspected of GMP violation filed at anti-corruption commission by Jeong Sae-im 2019-05-27 15:52
‘Shareholders can surely win lawsuit against Kolon’ by Jeong Sae-im 2019-05-24 19:34
라인
[News Focus] Kolon, regulator rapped for not doing enough to quell concerns of patients by Jeong Sae-im 2019-05-22 11:59
Legislator, activists call for revoking Invossa license, conducting probes by Jeong Sae-im 2019-05-21 16:03
[Reporter’s Notebook] ‘Wanna know what’s going on with MSD Korea?’ by Jeong Sae-im 2019-05-21 11:44
Kolon to follow 3,700 Invossa-treated patients for 15 years by Jeong Sae-im 2019-05-17 15:38
Will Celltrion CEO’s bet on ‘bio valley’ pay off? by Jeong Sae-im 2019-05-17 13:21
라인
CHA Biotech’s operating income plunges 92% in Q1 by Jeong Sae-im 2019-05-16 13:41
KangStem Biotech completes stem cell drug plant by Jeong Sae-im 2019-05-16 11:27
Samsung BioLogics in tight spot amid probe, shareholders’ lawsuit by Jeong Sae-im 2019-05-14 14:10
‘MSD Korea’s foreign exec got drunk, sexually harassed female worker’ by Jeong Sae-im 2019-05-14 11:53
Celltrion’s operating income down 33% in Q1 by Jeong Sae-im 2019-05-09 15:26
여백
여백
여백
Back to Top